Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $10.37 Million Position in Gilead Sciences, Inc. $GILD

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,484 shares of the biopharmaceutical company’s stock after acquiring an additional 5,990 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Gilead Sciences were worth $10,370,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Gilead Sciences by 54.0% in the 2nd quarter. Fisher Asset Management LLC now owns 10,700 shares of the biopharmaceutical company’s stock valued at $1,186,000 after purchasing an additional 3,750 shares during the last quarter. Finally, Westerkirk Capital Inc. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth $622,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Cantor Fitzgerald upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Leerink Partners boosted their target price on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Wolfe Research raised their price target on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 299,280 shares of company stock worth $42,820,550 in the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Ouro Medicines and struck a binding collaboration with Galapagos to advance T‑cell engager programs for autoimmune diseases — a clear push to expand its pipeline into potentially high‑value biologics and diversify beyond core antiviral franchises, which supports longer‑term growth expectations. Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
• Positive Sentiment: RBC noted decent patient persistence for Yeztugo (HIV prevention), indicating commercial uptake is intact even if market expansion is limited — positive for ongoing revenue stability from Gilead’s HIV portfolio. Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says
• Neutral Sentiment: Analysts expect single‑digit EPS growth for Q1 2026 — modest growth that keeps expectations muted vs. high‑growth peers but aligns with Gilead’s guidance and stable cash generation. This sets tempered near‑term performance expectations. Gilead Sciences’s Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Market roundups and earnings/transcript coverage show Gilead’s stock has risen in recent sessions but still lagged broader indices — reflecting investor caution despite positive headlines. These pieces mainly summarize momentum rather than introduce new catalysts. Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
• Neutral Sentiment: General investor commentary listing Gilead as an attractive dividend/ income name may support demand from income investors but is not an immediate catalyst for a large re‑rating. Markets Haven’t Changed. These 2 Cheap Dividends Still Rule
• Negative Sentiment: Gilead extended the tender offer for Arcellx at $115 plus a $5 CVR — the extension signals the deal hasn’t closed and increases short‑term uncertainty (and potential near‑term cash outflow). Investors may view extensions as a risk that the acquisition will be more costly, contested, or delayed. Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences Trading Up 0.7%

NASDAQ GILD opened at $140.30 on Thursday. The company has a market cap of $174.14 billion, a price-to-earnings ratio of 20.72, a price-to-earnings-growth ratio of 1.83 and a beta of 0.37. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The business’s fifty day moving average is $144.85 and its 200 day moving average is $129.14.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.